^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    CM350

    i
    Other names: CM350, CM-350
    Associations

    News

    Trials
    Company:
    Keymed Biosciences
    Drug class:
    CD3 agonist, GPC-3 inhibitor
    Related drugs:
    Associations

    News

    Trials
    7ms
    A Study of CM350 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=248, Recruiting, Keymed Biosciences Co.Ltd | N=92 --> 248 | Trial completion date: Mar 2025 --> Apr 2027 | Trial primary completion date: Mar 2025 --> Apr 2027
    Enrollment change • Trial completion date • Trial primary completion date
    |
    GPC3 (Glypican 3)
    |
    CM350
    over3years
    A Study of CM350 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=92, Recruiting, Keymed Biosciences Co.Ltd | Not yet recruiting --> Recruiting
    Enrollment open
    |
    GPC3 (Glypican 3)
    |
    GPC3 positive
    |
    CM350
    almost4years
    A Study of CM350 in Patients With Advanced Solid Tumors (clinicaltrials.gov)
    P1/2, N=92, Not yet recruiting, Keymed Biosciences Co.Ltd
    New P1/2 trial
    |
    GPC3 (Glypican 3)
    |
    GPC3 positive
    |
    CM350 • Kangyueda (stapokibart)